Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4794584 | 0.95 | MEN1 (0.48) | MEN1KMT2AHRH3PDE3BPDE3A | |
| Trifluoroacetic Acid SCHEMBL4765701 | 0.85 | MAPT (0.48) | MEN1KMT2AHRH3LMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL4765215 | 0.85 | SMN1; SMN2 (0.47) | HRH3MAPTABCB1NPC1ABCG2 | |
| Trifluoroacetic Acid SCHEMBL4770456 | 0.85 | NPC1 (0.52) | MEN1KMT2AHRH3MAPTNPC1 | |
| Trifluoroacetic Acid SCHEMBL4772070 | 0.84 | KMT2A (0.50) | MEN1KMT2AHRH3LMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL4772037 | 0.81 | SLC2A1 (0.43) | MEN1KMT2AHRH3MAPTNPC1 | |
| Trifluoroacetic Acid SCHEMBL4770760 | 0.80 | HRH3 (0.50) | HRH3MAPTABCB1NPC1ABCG2 | |
| Trifluoroacetic Acid SCHEMBL4774158 | 0.80 | TMPRSS2 (0.55) | MEN1KMT2AMAPTABCB1NPC1 | |
| SCHEMBL4770767 | 0.79 | HRH3 (0.42) | MEN1KMT2AHRH3SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL4767946 | 0.79 | HRH3 (0.56) | KMT2AHRH3MAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | MEN1 2213/4885KMT2A 99/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.